MDICT Task Force

The Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT) is an international task force of leading investigators and senior industry employees in charge of the clinical development of anticancer agents. MDICT's mission is to develop practical guidance for the optimal development of innovative anticancer agents, in particular targeted agents. The group is chaired by drs. Elizabeth Eisenhauer (Canada), Giuseppe Giaccone (USA) and Hilary Calvert (UK), and is supported administratively by Marinus Lobbezoo (Netherlands) and logistically by Congress by design (Netherlands), the congress agency of the TAT Congress series. Verbal reports of MDICT Task Force meetings are always presented in a plenary sesssion of the ensuing TAT congress. These presentations are accessible via the "TAT slides" buttons on the right hand side of this page. Several MDICT reports have been published in full (see below).

Annual meetings
The Task Force meets annually in conjunction with the TAT meeting. Participation is by invitation only.

Joining MDICT
Professionals with a senior role in oncology drug development in academia, industry, governmental or regulatory agencies are invited to submit an application for membership. If you are interested in joining, submit your CV and a brief motivation to the TAT Secretariat at Congress by design ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ). 

MDICT reports
Reports of MDICT meetings held in 2006 - 2012 have been published (1-5). No MDICT meeting was held in 2013. A review of the first years of MDICT has been published (6).

1. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2008;44:19-24. Abstract.

2. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK. Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 2008;44:25-29. Abstract.

3. Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G. Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2009;45:741-746. Abstract.

4. Goodwin R, Giaccone G, Calvert H, Lobbezoo M, Eisenhauer EA. Targeted agents: How to select the winners in preclinical and early clinical studies? Eur J Cancer 2011;48:170-178. Abstract.

5. Seymour LK, Calvert AH, Lobbezoo MW, Eisenhauer EA, Giaccone G. Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2013;49:1808-1814. http://dx.doi.org/10.1016/j.ejca.2013.01.014

6. Lobbezoo MWCalvert AHEisenhauer EA, Giaccone G. MDICT Task Force addresses methodological issues in the clinical development of innovative cancer therapies. Clinical Invest 2012;2:133–138. 

TAT 2014 abstracts
Download PDFs

TAT 2014 presentations
(PDF version)

TAT 2013 abstracts
Ann Oncol 2013 (Suppl)

TAT 2013 presentations
(PDF version)

TAT 2012 abstracts
Ann Oncol 2012 (Suppl)